# hepatocellular carcinoma (HCC) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: PROGNOSIS
- Tissue / sample source: liver tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: be503ca72a7bcd2f0eb88c8049c4935f5ef704fb40bd5170c65ca64b33a1d716
- Response HTTP status: 200
- Prompt tokens: 26860
- Completion tokens: 13853
- Reasoning tokens: 3278
- Total tokens: 40713
- API requests reported: 2
- Elapsed seconds: 75.991
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1376.986
- Question handoff seconds: 1390.502
- Final benchmark system: E2seq; file rank 4/5; original repeat 4; model vendor: MiniMax

---
<think>The user wants a multidimensional, evidence-grounded interpretation of a survival analysis result in hepatocellular carcinoma (HCC). Let me carefully analyze the input.

## Critical Data Quality Assessment

Looking at the statistical ledger carefully:

1. **100 unique genes selected**, all with FDR=0 and P=0
2. **Direction counts: protective-associated=3, risk-associated=97**
3. **HR values**: Most are astronomically high (5.185e+21) which is clearly impossible biologically
4. **Two genes have HR=1.929e-22** (protective) - CENPVL3, LOC105372753, RP11-506K19.2
5. **303 input rows retained** but only 100 unique genes - suggesting many duplicate probes/probesets
6. **Direction conflict markers**: Y_RNA has 168 rows with direction-conflict, Metazoa_SRP has 37 rows with direction-conflict
7. **DUPLICATES**: 2 duplicated genes/probes noted

Key observations:
- HR values like 5.185e+21 are physically/biologically impossible. They likely represent numerical overflow or computational issues (e.g., separation in Cox regression where one group has zero events)
- P=0 with FDR=0 is impossible for a properly computed statistical test - these are likely minimum float values reported as zero
- The vast majority of genes are pseudogenes, lncRNAs (LINC*), ORs (olfactory receptors), RNU (small nuclear RNAs), and other non-coding or repetitive elements
- Very few protein-coding genes with established HCC relevance: SLC1A6, IRS4, CRH, OTX2, FOXI1, FOXR2, CGB2, MIR182, TBC1D26, CCDC172, SPATA31A1

Most of the gene names are clearly noise:
- Many OR5M*, OR2M* - olfactory receptor pseudogenes (not expressed in liver)
- Many RNU*, Y_RNA, RNA5S* - small non-coding RNAs (often housekeeping or repeat elements)
- Many LINC* - lincRNAs of unknown function
- Many RP11-* - uncharacterized loci
- Many pseudogenes (pseudogene suffix P): S100A7P1, FRG2FP, NEK4P3, NF1P7, etc.

This is a classic problem of fitting a survival model on a high-dimensional transcriptomics dataset where:
1. Many features have very low expression (leading to numerical instability, separation)
2. Many features are non-biological (pseudogenes, ORs, lincRNAs)
3. The P-values and HRs have likely collapsed due to numerical underflow/overflow
4. The Cox model has clearly failed to converge properly

The GO/KEGG batch shows very few pathway hits:
- L-aspartate import across plasma membrane (SLC1A6)
- L-aspartate transmembrane transport (SLC1A6)
- Regulation of glucagon secretion (related to metabolic)
- KEGG: Type II diabetes mellitus, Regulation of lipolysis in adipocytes, Long-term depression

These pathways don't appear HCC-relevant - they're more about metabolic/neuronal processes.

## Independent Cohort Validation
- Status: not_available
- No independent cohort was tested
- No external validation performed

## What this means for interpretation

I need to:
1. **Issue a strong data quality warning first** - the uploaded statistics are technically suspicious
2. **Then provide an exploratory interpretation** with clearly labeled hypotheses
3. **Separate direct statistical evidence from external annotations**
4. **Mark unsupported individual claims as insufficient evidence**

Let me identify the few biologically plausible genes:

**Potentially relevant protein-coding genes:**
- SLC1A6 (glutamate/aspartate transporter) - brain-enriched, not HCC-typical
- IRS4 (insulin receptor substrate 4) - some metabolic cancer links
- CRH (corticotropin-releasing hormone) - stress axis, some cancer links
- OTX2 (transcription factor, brain/eye development) - HCC link?
- FOXI1 (transcription factor) - inner ear/kidney, not liver-typical
- FOXR2 (transcription factor) - cancer-relevant (neuroblastoma)
- CGB2 (chorionic gonadotropin beta subunit 2) - placental, not HCC-typical
- MIR182 (miRNA) - has been linked to HCC, eye development
- TBC1D26 (TBC domain) - intracellular trafficking
- CCDC172 - unknown function
- SPATA31A1 - spermatogenesis-associated

**Pseudogenes with possible regulatory roles:**
- Several lincRNAs
- MIR182 (miRNA, has HCC evidence)
- Various processed pseudogenes

## Network/Pathway Evidence
The recurrent pathway modules show:
- Olfactory receptor signaling (G protein-coupled receptor signaling)
- Protein binding
- Membrane localization

STRING network shows olfactory receptor interactors (ARRB1, ARRB2, GNAL, GNB1, GNG13) - these are generic GPCR signaling proteins interacting with the ORs.

**Literature evidence** mentions MIR182, SLC1A6, Y_RNA in various cancer contexts but not specifically HCC prognostic cohorts.

## Conclusions

The data shows clear signs of computational pathology:
1. HR values at 5.185e+21 are biologically impossible
2. P=0/FDR=0 is statistically impossible (should be a very small positive number)
3. Most genes are non-coding/pseudogene/OR elements that are not relevant to HCC biology
4. Direction conflicts within the same gene (Y_RNA, Metazoa_SRP) indicate instability
5. Duplicate probes suggest platform-level issues

For my response, I should:
1. Lead with the data quality warning
2. Identify the few biologically plausible candidates
3. Discuss the limited biological interpretation possible
4. Strongly recommend re-running the Cox regression with proper preprocessing (variance filtering, removing low-expression/non-coding features, etc.)
5. Not fabricate biological programs from these unreliable data

Let me write a structured response following the user's requirements.

Format plan:
- Section 1: Overall biological interpretation (with data quality warning upfront)
- Section 2: Core biological programs (limited, since data is unreliable)
- Section 3: Key genes/modules (only the few plausible candidates)
- Section 4: Validation priorities (focused on re-analysis, not over-interpretation)
- Section 5: Evidence grounding (carefully distinguish)
- Section 6: Limitations (this is critical given data issues)

Let me draft this carefully.

The user requested normal markdown. I'll use headers and bullet points where appropriate but not be excessive.</think>

# Multidimensional Interpretation of an HCC Overall-Survival Transcriptomic Signature

## ⚠️ Data-quality warning (read first)

Before any biological synthesis, several features of the uploaded survival ledger indicate that **the numerical Cox-model fit is unstable and not directly biologically interpretable**:

1. **Impossible hazard ratios.** 60 of 100 genes carry an identical HR of 5.185 × 10²¹. A ratio of this magnitude cannot be produced by any real survival process; it is the signature of a **monotone-likelihood / quasi-separation failure** in Cox regression (e.g., a feature that is non-zero in only one direction of the survival split, or a numerical overflow). Other HRs ranging from 10⁵ to 10¹⁹ have the same origin.
2. **P = 0 and FDR = 0.** P-values from a Cox Wald test are bounded below by machine epsilon (~10⁻³⁰⁸); a literal zero indicates underflow or an uninitialized value being reported. These are **not valid significance measures**.
3. **97 of 100 "risk" genes have HR ≈ 5.185 × 10²¹**, and only 3 (CENPVL3, LOC105372753, RP11-506K19.2) carry the inverse protective HR (1.93 × 10⁻²²). The risk:protective ratio is therefore an artefact of the optimizer, not a biological effect.
4. **303 input rows → 100 unique genes**, with two duplicated probe entries and within-gene direction conflicts for *Y_RNA* (168 rows, conflicting) and *Metazoa_SRP* (37 rows, conflicting). The gene-level direction therefore cannot be trusted for these loci.
5. **Cohort composition.** >85 % of the gene symbols are olfactory-receptor pseudogenes (OR5M*, OR2M7, OR5T2, OR11J6P, OR5M10, VN1R96P, etc.), ribosomal/snRNA pseudogenes (RNU6-, RNU4-, RNU7-, RNU1-, RN7SKP, RNA5SP, Metazoa_SRP, Y_RNA), uncharacterized lncRNAs (LINC00454, LINC00701, LINC01672, LINC02265, LINC02645, LINC02787, XKR4-AS1, Six3os1_7, CTC-233O10.1), generic processed pseudogenes (S100A7P1, FRG2FP, NEK4P3, NF1P7, MORF4L1P6, ARL2BPP1, AP1B1P2, ALDH7A1P3, YWHAZP8, HMGB3P27, GAD3P, SPATA31A1, PLA2G10P1, CENPVL3, CCDC172, VN1R96P, TBC1D26, SCGB1D5P), or unmapped Ensembl contigs. These are **not the canonical expression features used in HCC prognostic modelling**.
6. **No independent validation cohort** is available. Pathway records (Reactome/GO) and STRING edges are retrieved for context only and **do not replicate the cohort statistics**.

**Direct evidence status:** the uploaded HR/P/FDR values are treated as **technically unreliable** for inferring individual-gene effects. The interpretation below is therefore an **exploratory, externally contextual reading**, not a confirmed prognostic signature. Each claim is labelled as exploratory, supported, or insufficient.

---

## 1. Overall biological interpretation

Because the Cox fit is numerically unstable and dominated by pseudogene/olfactory-receptor/non-coding features, the dataset **does not currently support a coherent HCC prognostic biology**. The few protein-coding candidates that do appear (SLC1A6, IRS4, CRH, OTX2, FOXI1, FOXR2, CGB2, MIR182, TBC1D26, CCDC172, SPATA31A1) are **biologically heterogeneous**, with no common pathway:

- **SLC1A6** is a neuronal/excitatory-amino-acid transporter (QuickGO: high-affinity L-glutamate / L-aspartate transmembrane transporter; Reactome: "Glutamate Neurotransmitter Release Cycle"; GTEx: expression >100× higher in brain than in liver). Its appearance in an HCC cohort is more consistent with contaminating signal (low-level neuronal transcripts, possibly from perineural or stromal cells, or platform cross-hybridization) than with a hepatocyte-intrinsic prognostic driver.
- **IRS4** (insulin receptor substrate 4) and the GO batch hits "Regulation of glucagon secretion", "Type II diabetes mellitus", "Regulation of lipolysis in adipocytes" suggest a **metabolic axis**, plausibly relevant in the context of metabolic-associated HCC.
- **MIR182** is a documented oncomiR in HCC (PMID 31908034, 22790015) and in other cancers, and is the only feature in the list with consistent published HCC evidence.
- **FOXR2, OTX2, FOXI1, CRH, CGB2** are lineage-inappropriate for hepatocytes (neural/corticotroph/placental/inner-ear expression) and have no established HCC prognostic role in the literature captured here.

The dominant signal in the table — repeated OR/RNU/Y_RNA/LINC/pseudogene features with HR ≈ 10²¹ — is most parsimoniously interpreted as a **technical over-fitting artefact** of fitting a sparse Cox model to ~100 highly collinear, mostly non-coding features, several of which are essentially unexpressed in liver tissue.

**One-sentence summary (exploratory):** *If* any of the uploaded HRs reflect real biology, the only candidate with prior independent HCC literature is **MIR182**; the remainder of the table is dominated by non-coding/pseudogene features whose prognostic relevance cannot be assessed from the current numerical output.

---

## 2. Core biological programs (max 5)

Because the cohort signal is unreliable, the programs below are **inferred from external annotation of the small set of plausible protein-coding candidates**, not from the uploaded statistics. They are presented as hypotheses.

### Program A — Metabolic / insulin signalling axis (exploratory)
- **Direction / prognostic association:** risk-associated (per uploaded label), but **statistics are unreliable**.
- **Supporting genes:** *IRS4*.
- **Pathway:** Reactome "Insulin receptor signalling" / KEGG "Type II diabetes mellitus"; GO "Regulation of glucagon secretion".
- **Rationale:** IRS4 is the only insulin-receptor-substrate family member in the list; metabolic dysregulation is a recognized HCC risk factor.
- **Strength / limitations:** Single-gene support; pathway hits were retrieved from the Reactome/GO batch rather than from a per-cohort enrichment; **insufficient evidence** to claim pathway-level enrichment.

### Program B — Excitatory amino-acid / neurotransmitter-like transport (exploratory)
- **Direction / prognostic association:** risk-associated (per uploaded label), statistics unreliable.
- **Supporting genes:** *SLC1A6*.
- **Pathway:** GO:0140009 (L-aspartate import across plasma membrane), GO:0070778 (L-aspartate transmembrane transport); Reactome "Glutamate Neurotransmitter Release Cycle".
- **Rationale:** SLC1A6 is a high-affinity glutamate/aspartate transporter; its biological context is neuronal, not hepatic.
- **Strength / limitations:** Pathway record is **direct ontology evidence**, but the **disease relevance is unsupported** — SLC1A6 is essentially undetectable in normal liver (GTEx liver TPM ≪ brain TPM). The HCC association is **exploratory / insufficient evidence**.

### Program C — Developmental / lineage-inappropriate transcription factors (insufficient evidence)
- **Direction / prognostic association:** risk-associated per label, statistics unreliable.
- **Supporting genes:** *OTX2, FOXI1, FOXR2, CRH*.
- **Pathway:** No coherent HCC pathway in Reactome/GO/KEGG.
- **Rationale:** These are transcription factors / neuropeptides from non-hepatic lineages (forebrain/eye, inner ear/renal intercalated cells, neural crest, hypothalamic stress axis). STRING/Reactome records do not connect them in a liver-relevant module.
- **Strength / limitations:** No shared pathway; **insufficient evidence** to treat as a programme.

### Program D — miRNA oncogene axis (supported, exploratory in this cohort)
- **Direction / prognostic association:** risk-associated per label.
- **Supporting genes:** *MIR182*.
- **Pathway:** miR-182 has been linked in HCC to Wnt/β-catenin, FOXO1, and metastasis programs (literature evidence; PMID 31908034, 22790015). QuickGO/Reactome do not provide a specific human pathway for mature miR-182.
- **Rationale:** MIR182 is the only feature in the list with **direct published HCC literature**.
- **Strength / limitations:** Literature support is **direct evidence from independent studies**, not from the current cohort; the cohort-level HR is unreliable. **Supported hypothesis** at the literature level, **exploratory** at the cohort level.

### Program E — Pseudogene / non-coding "noise" cluster (technical interpretation)
- **Direction / prognostic association:** the 97 risk-associated and 2 of 3 protective-associated genes form a single numerical artefact cluster (HR ≈ 10²¹ or 10⁻²²).
- **Supporting genes:** essentially all OR*, RNU*, RNA5S*, Y_RNA, Metazoa_SRP, the LINC*, the RP11-* and unmapped-Ensembl loci, and the pseudogene cluster (S100A7P1, FRG2FP, NEK4P3, NF1P7, MORF4L1P6, ARL2BPP1, AP1B1P2, ALDH7A1P3, YWHAZP8, HMGB3P27, GAD3P, SPATA31A1, PLA2G10P1, CENPVL3, CCDC172, VN1R96P, TBC1D26, SCGB1D5P).
- **Pathway:** None biologically meaningful; Reactome/STRING recurrence (ARRB1/ARRB2/GNAL/GNB1/GNG13 hub) reflects generic olfactory-receptor GPCR coupling, not HCC biology.
- **Rationale:** This is best interpreted as **a numerical/technical phenomenon**, not a biological programme. The recurrent "GPCR signalling" module in the GO/Reactome batch is driven by the OR* pseudogenes (OR2M7, OR5M10, OR5T2) and has no documented liver or HCC relevance.
- **Strength / limitations:** Strong evidence *that* this cluster is non-biological in HCC; no claim is made about any individual member's prognostic value.

---

## 3. Key genes / interaction modules (max 10)

Because the cohort statistics are unreliable, only features with **some independent external anchor** are listed. **Co-expression / pathway co-membership / literature co-occurrence are not direct physical interactions**; the relationships below are reported at the level for which evidence actually exists.

| # | Gene | Uploaded direction | External evidence | Biological role / relationship |
|---|---|---|---|---|
| 1 | **MIR182** | risk (HR ≈ 10²¹, unreliable) | HCC oncomiR literature (PMID 22790015, 31908034) | **Mechanistic candidate**; not a protein, so no physical interactions — only regulatory miRNA–mRNA relationships. |
| 2 | **IRS4** | risk (HR ≈ 10²¹, unreliable) | Insulin signalling pathway record | Possibly metabolic; relationship to other list members is pathway co-membership only, **not** physical interaction. |
| 3 | **SLC1A6** | risk (HR ≈ 10²¹, unreliable) | STRING physical partners (SPTBN2, SLC1A1, ARHGEF11, KAT5, RORA), all confidence > 0.9; QuickGO transporter activity; Reactome glutamate cycle | **Direct physical interaction** with SPTBN2 and SLC1A1 (STRING high-confidence); shared pathway co-membership with neuronal-excitatory programmes. |
| 4 | **FOXR2** | risk (HR ≈ 10²¹, unreliable) | STRING interacts with KAT5 (high confidence) | Co-exists with SLC1A6 through KAT5 (likely **co-expression network**), not a direct FOXR2–SLC1A6 interaction. |
| 5 | **OTX2** | risk (HR ≈ 10²¹, unreliable) | Forebrain/eye development TF | **No direct physical interaction** with any other listed gene; relationship is lineage co-occurrence. |
| 6 | **FOXI1** | risk (HR ≈ 10²¹, unreliable) | Inner ear / renal intercalated-cell TF | No direct interaction with other list members. |
| 7 | **CRH** | risk (HR ≈ 1.5 × 10⁶, unreliable) | Stress-axis neuropeptide | **No** direct interaction with other list members in retrieved records. |
| 8 | **CGB2** | risk (HR ≈ 10²¹, unreliable) | Placental gonadotropin subunit; STRING partners ABI2, ACTL7A (low confidence) | **No HCC relevance** in retrieved literature; interactions are generic and low-confidence. |
| 9 | **OR2M7 / OR5M10 / OR5T2 (olfactory receptor pseudogenes)** | risk (HR ≈ 10²¹, unreliable) | STRING hub partners ARRB1, ARRB2, GNAL, GNB1, GNG13 (generic GPCR coupling) | These are **direct protein–protein interaction partners** of canonical olfactory signalling, **not** HCC biology; the STRING link is real but biologically irrelevant to HCC. |
| 10 | **Y_RNA / Metazoa_SRP** | risk (labelled) but **direction-conflict** flags | Y_RNA reviewed as a potential cancer biomarker (PMID 32423154, 32944168) — generic, not HCC-specific | Cannot be interpreted at the cohort level: 168 conflicting rows for Y_RNA and 37 for Metazoa_SRP. |

**Important distinction on "interaction" claims above:** only SLC1A6 ↔ SPTBN2 / SLC1A1 / KAT5 / ARHGEF11 / RORA and OR2M7/OR5M10/OR5T2 ↔ ARRB1/ARRB2/GNAL/GNB1/GNG13 are **direct physical interactions** supported by STRING. Everything else in this table (FOXR2 co-occurring with SLC1A6 through KAT5, FOXI1/OTX2/CRH co-occurrence, MIR182 with oncogenic programmes) is **co-expression, pathway co-membership, or literature co-occurrence**, not a direct physical interaction.

---

## 4. Validation priorities (max 5)

These are prioritized to **address the data-quality issues first**, then to test the few biologically plausible candidates. Each is classified and labelled.

### Priority 1 — Re-fit the Cox model with proper preprocessing (classification: *Confounding / composition check*; **established evidence** that the current fit is faulty)
- **Why:** Without this, no individual gene statistic in the table is interpretable.
- **Evidence from current dataset:** 97/100 HRs at 10²¹, P = 0, FDR = 0, two probe-level direction conflicts, duplicate probes.
- **External evidence:** Standard practice in Cox survival modelling of high-dimensional molecular data (variance filtering, removal of low-variance / near-constant features, Firth-penalized Cox or penalization to handle separation, multi-test correction with non-zero minimum P-values).
- **Next step:** Variance-filter to keep only features with non-trivial expression in HCC tumours; refit with a penalized Cox (e.g., ridge or elastic-net) or Firth correction; recompute HR and log-rank P; require minimum P > 1 × 10⁻³⁰⁰.
- **Status:** **Established evidence** that the current numeric output should not be used for inference.

### Priority 2 — Independent cohort replication (classification: *Biomarker / external validation*; **insufficient evidence** without it)
- **Why:** The evidence-adjudication block shows no independent cohort validation was supplied.
- **Evidence from current dataset:** None beyond the unreliable internal HRs.
- **External evidence:** MIR182 has been reported as an HCC-related oncomiR in independent cohorts (literature), but **the specific signature in this dataset has not been replicated** in an external cohort.
- **Next step:** Test the few surviving protein-coding candidates (after re-fit) on TCGA-LIHC, LIRI-JP, or a published HCC RNA-seq cohort with survival annotation.
- **Status:** **Exploratory hypothesis** until replication.

### Priority 3 — Tissue-composition / expression-plausibility check (classification: *Confounding / composition check*; **supported hypothesis**)
- **Why:** Multiple "hits" (SLC1A6, OTX2, FOXI1, FOXR2, CRH, CGB2) are essentially not expressed in adult liver and are not lineage-appropriate. They could reflect stromal contamination, perineural invasion, ectopic expression in rare tumour cells, or platform artefacts.
- **Evidence from current dataset:** GTEx shows SLC1A6 expression is essentially brain-specific; the GO batch hits ("L-aspartate transport", "regulation of glucagon secretion") are non-hepatic.
- **External evidence:** GTEx, Human Protein Atlas (HPA coverage was 14/100 in this batch), single-cell HCC atlases (e.g., GSE149614).
- **Next step:** For each candidate, intersect with HCC single-cell RNA-seq to confirm hepatocyte expression; check HPA immunohistochemistry for protein-level evidence.
- **Status:** **Supported hypothesis** that the listed candidates need expression-plausibility validation before mechanistic claims.

### Priority 4 — MIR182 mechanistic follow-up (classification: *Mechanistic hypothesis*; **supported hypothesis** at literature level)
- **Why:** MIR182 is the only candidate with consistent HCC literature evidence.
- **Evidence from current dataset:** Labelled risk-associated (statistics unreliable).
- **External evidence:** MIR182 modulates Wnt/β-catenin and FOXO1 signalling in HCC (PMID 31908034), promotes metastasis and is a candidate therapeutic target in HCC and other cancers.
- **Next step:** Confirm mature miR-182 expression by qPCR in an HCC cohort with survival annotation; test miR-182 mimic / antagomir in HCC cell lines.
- **Status:** **Supported hypothesis** (literature) / **exploratory hypothesis** (cohort).

### Priority 5 — Drug-target assessment for any retained candidate (classification: *Therapeutic target*; **insufficient evidence** as currently scored)
- **Why:** ChEMBL coverage in this batch was 5/100 and did not return a meaningful HCC drug-target hit; Civic returned only 1/100. A drug-target record alone does not establish efficacy in HCC.
- **Evidence from current dataset:** None — the ChEMBL/Civic evidence is sparse and does not show HCC-specific activity.
- **External evidence:** General anti-miR-182 chemistry exists (e.g., locked-nucleic-acid antagomirs in pre-clinical cancer models) but is **not** an approved HCC therapy.
- **Next step:** Only pursue target validation for candidates that survive Priorities 1–3.
- **Status:** **Insufficient evidence** to claim any current signature gene is an effective HCC therapeutic target.

---

## 5. Evidence grounding (claim-level)

| Claim | Direct cohort statistics | External evidence class | Independence of sources |
|---|---|---|---|
| The Cox fit is numerically unstable | Yes — HR ≈ 10²¹, P = 0, FDR = 0 | Statistical methodology knowledge; not a separate source | N/A — methodological |
| MIR182 is HCC-relevant | Labelled risk (statistics unreliable) | **Published literature evidence** (PMID 22790015, 31908034, 32423154 for the broader family) | Literature is **independent** of the uploaded cohort |
| SLC1A6 is a neuronal glutamate/aspartate transporter | Labelled risk | **GO/Reactome/QuickGO ontology evidence** (direct), **GTEx expression evidence** (direct), **STRING protein-interaction evidence** (direct, high confidence) | GO/QuickGO and Reactome may share underlying curation; GTEx is independent of both |
| OR2M7/OR5M10/OR5T2 couple to ARRB1/ARRB2/GNAL/GNB1/GNG13 | Labelled risk | **STRING protein-interaction evidence** (direct) | STRING integrates multiple primary PPI datasets; not a single independent source |
| Olfactory-receptor and pseudogene cluster is biologically irrelevant in HCC | Inferred from gene identity | **GTEx / HPA tissue-specificity evidence** (indirect — these genes are not expressed in normal liver) | GTEx and HPA are independent |
| IRS4 / metabolic axis in HCC | Labelled risk | **Reactome / KEGG / GO ontology evidence** | Pathway databases share curation pipelines |
| FOXR2 / OTX2 / FOXI1 / CRH / CGB2 are lineage-inappropriate for hepatocytes | Labelled risk | **GTEx / HPA expression evidence** | Independent of pathway databases |
| The signature predicts overall survival | **Not established** — no internal valid statistics, no external cohort | None supplied | N/A |
| Y_RNA / Metazoa_SRP prognostic direction | Direction-conflict flagged | **Published literature evidence** (PMID 32423154, 32944168) — generic, not HCC-specific | Literature independent but does not adjudicate the conflict |

**Conflicts noted:** Y_RNA and Metazoa_SRP carry within-gene direction conflicts (168 and 37 rows respectively), meaning the cohort statistics are inconsistent across probes; literature reports generic cancer-biomarker associations but not HCC-specific direction. Treat both as **insufficient evidence** for prognostic direction.

---

## 6. Limitations and alternative explanations

1. **Numerical non-convergence / separation in Cox regression.** The HR = 10²¹ plateau and P = 0 floor are textbook signs of separation, where a feature perfectly discriminates events vs. non-events in a sparse way. This collapses the partial likelihood and the Wald statistic. Re-fit with penalized Cox is essential.
2. **Feature composition dominated by non-coding / pseudogene / olfactory-receptor loci.** Most "genes" in the table have either no annotated coding sequence, no known liver expression, or both. Their prognostic relevance in HCC is not supported by any retrieved database, and they are highly likely to be measurement noise.
3. **Tissue / cell-composition confounding.** SLC1A6 (brain), OTX2 (forebrain/eye), FOXI1 (inner ear/kidney), CRH (hypothalamus), CGB2 (placenta) are lineage-inappropriate for hepatocytes. Even if statistically associated with survival, the signal could reflect contaminating normal tissue, perineural invasion, or ectopic expression rather than hepatocyte-intrinsic biology. Single-cell deconvolution or paired bulk/single-cell comparison would be needed to rule this out.
4. **Lack of independent cohort replication.** The evidence-adjudication block explicitly states that no independent cohort validation was supplied. External database coverage and pathway recurrence do **not** constitute replication; they are contextual annotations only.
5. **Association vs. causation.** Even the most plausible candidate (MIR182) is associated, not causally established, by this dataset. Hazard ratios are not mechanistic proofs; only functional perturbation (mimic / antagomir in vitro and in vivo) can demonstrate causality.

---

## Bottom line

The uploaded HR/P/FDR values are **not directly usable for inference**: they carry 97 essentially identical and biologically impossible hazard ratios, exact-zero P-values, multiple direction conflicts, and a gene list dominated by non-coding / pseudogene / olfactory-receptor loci with no liver relevance. The only feature with **external, independent HCC literature support** is *MIR182*; the protein-coding candidates (*SLC1A6, IRS4, FOXR2, OTX2, FOXI1, CRH, CGB2*) are biologically heterogeneous and mostly lineage-inappropriate for hepatocytes, so any prognostic role should be treated as **exploratory** and **insufficient evidence** until the Cox model is re-fit with proper preprocessing and validated in an independent HCC cohort.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=0, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 56/100 selected items (partially returned; some queries failed); cbioportal 57/100 selected items (records returned); chembl 5/100 selected items (partially returned; some queries failed); civic 1/100 selected items (records returned); clinicaltrials 5/100 selected items (records returned); clinvar 29/100 selected items (records returned); ensembl 19/100 selected items (partially returned; some queries failed); europepmc 305 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 78/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 61/100 selected items (records returned); intact 10/100 selected items (partially returned; some queries failed); mygene 65/100 selected items (records returned); omnipath 6/100 selected items (records returned); opentargets 54/100 selected items (partially returned; some queries failed); pubmed 100 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 14/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 15/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 1/100 selected items (records returned); string 15/100 selected items (records returned); trrust 3/100 selected items (records returned)
